Get the Stockscreener App
85.59
0.71%
-0.615
After Hours:
85.59
Kymera Therapeutics Inc stock is traded at $85.59, with a volume of 485.14K.
It is down -0.71% in the last 24 hours and up +4.11% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
See More
Previous Close:
$86.20
Open:
$86.27
24h Volume:
485.14K
Relative Volume:
0.86
Market Cap:
$7.04B
Revenue:
$51.48M
Net Income/Loss:
$-315.00M
P/E Ratio:
-23.97
EPS:
-3.5708
Net Cash Flow:
$-244.00M
1W Performance:
+15.74%
1M Performance:
+4.11%
6M Performance:
-0.11%
1Y Performance:
+82.26%
1-Day Range:
$84.84
$88.59
1-Week Range:
$73.05
$88.59
52-Week Range:
$36.65
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
85.59 | 7.09B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-03-25 | Resumed | Guggenheim | Buy |
| Oct-24-25 | Reiterated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-18-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Maven Securities LTD Takes $1.17 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by First Turn Management LLC - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Eventide Asset Management LLC - MarketBeat
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
Kymera Therapeutics, Inc. $KYMR Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
Kymera presents KT-621 phase 1 data in Japanese adults By Investing.com - Investing.com Australia
Kymera reports positive KT-621 phase 1 Japanese study results - grafa.com
Kymera presents KT-621 phase 1 data in Japanese adults - Investing.com
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting - GlobeNewswire Inc.
Monashee Investment Management LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting - Investing News Network
Brookline Capital Markets Increases Price Target for Kymera Therapeutics (KYMR) - Insider Monkey
Assessing Kymera Therapeutics (KYMR) Valuation After Recent Share Price Rebound - Yahoo Finance
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study - TradingView
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
Kymera’s KT-485 Enters Phase 1 Trial Under $20M Sanofi Deal - The Clinical Trial Vanguard
Brookline Capital raises Kymera stock price target on lupus drug data By Investing.com - Investing.com Australia
Kymera receives $20m milestone from Sanofi for trial start - Investing.com UK
Kymera’s KT-579 shows promise for SLE treatment - BioWorld News
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration - Investing News Network
Kymera receives $20m milestone from Sanofi for trial start By Investing.com - Investing.com India
Sanofi-led trial of new oral inflammation drug ties to $975M - Stock Titan
Kymera Therapeutics, Inc. $KYMR Position Increased by Capital Research Global Investors - MarketBeat
Kymera Therapeutics (KYMR) Unveils Promising Preclinical Data on KT-579 for Lupus Treatment - GuruFocus
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations - Investing News Network
Kymera appoints Penny Carlson as SVP of development operations - Investing.com UK
Kymera appoints Penny Carlson as SVP of development operations By Investing.com - Investing.com South Africa
Kymera Therapeutics' Jeremy Chadwick to Retire as COO, Will Remain as Advisor - TradingView
COO Jeremy Chadwick to retire from Kymera Therapeutics (NASDAQ: KYMR) - Stock Titan
New Kymera trials chief steps in as COO Jeremy Chadwick retires - Stock Titan
Brookline Capital raises Kymera stock price target on lupus drug data - Investing.com Nigeria
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses - Investing News Network
Kymera presents preclinical data for lupus drug KT-579 - Investing.com UK
Kymera presents preclinical data for lupus drug KT-579 By Investing.com - Investing.com South Africa
Kymera tests oral IRF5 degrader that reduced lupus markers in lab models - Stock Titan
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $110.31 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Sanofi and Kymera Advance SAR447971 Into First-in-Human Trial, Setting Up New Optionality in Inflammatory Skin Disease - TipRanks
(KYMR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How The Kymera Therapeutics (KYMR) Investment Narrative Is Evolving Without New Analyst Targets - Yahoo Finance
Kymera Therapeutics (KYMR) CFO exercises stock options, boosting direct holdings - Stock Titan
Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord? - Insider Monkey
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):